PD81723
Based on 1 Customer Validation
PD81723 is an adenosine receptor binding enhancer. PD81723 enhances the inhibition of exogenous adenosine in a dose-dependent manner in hippocampal brain sections.
For research use only. We do not sell to patients.
- Purity: 99.63%
- CAS No.: 132861-87-1
- Formula: C14H12F3NOS
- Molecular Weight:299.31
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
GPCR/G Protein Compound Library
HY-L006
-
Small Molecule Immuno-Oncology Compound Library
HY-L031
-
Neurotransmitter Receptor Compound Library
HY-L062
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Lactylation Compound Library
HY-L249
All Adenosine Receptor Isoforms
More
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO | EC50 |
1.7 μM
Compound: PD-81723
|
Displacement of [3H]CCPA from human adenosine A1 receptor expressed in CHO cells by scintillation counting
Displacement of [3H]CCPA from human adenosine A1 receptor expressed in CHO cells by scintillation counting
|
[PMID: 20345101] |
| CHO-K1 | EC50 |
13.6 μM
Compound: 1, PD-81723
|
Modulation of human adenosine A1 receptor expressed in CHO-K1 cells assessed as allosteric effect on [125I]ABA dissociation
Modulation of human adenosine A1 receptor expressed in CHO-K1 cells assessed as allosteric effect on [125I]ABA dissociation
|
[PMID: 18771255] |
| CHO-K1 | EC50 |
8.4 μM
Compound: PD-81723
|
Effective dose as dissociation of [3H]N6-cyclohexyladenosine ([3H]CHA) from CHO-K1 membrane after treatment with allosteric enhancer and (R)-PIA
Effective dose as dissociation of [3H]N6-cyclohexyladenosine ([3H]CHA) from CHO-K1 membrane after treatment with allosteric enhancer and (R)-PIA
|
[PMID: 12723950] |
| CHO-K1 | ED50 |
13.6 μM
Compound: 1, PD-81723
|
Activity at human adenosine A1 receptor expressed in CHOK1 cells assessed as agonist-receptor ternary complex remaining by [35S]GTPgammaS binding assay
Activity at human adenosine A1 receptor expressed in CHOK1 cells assessed as agonist-receptor ternary complex remaining by [35S]GTPgammaS binding assay
|
[PMID: 17980606] |
Chemical Information
-
CAS No. 132861-87-1
-
Appearance Solid
-
Molecular Weight 299.31
-
Formula C14H12F3NOS
-
Color yellow
-
SMILES
O=C(C1=C(N)SC(C)=C1C)C2=CC=CC(C(F)(F)F)=C2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : 100 mg/mL (334.10 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.35 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (272 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.3410 mL | 16.7051 mL | 33.4102 mL | 83.5254 mL |
| 5 mM | 0.6682 mL | 3.3410 mL | 6.6820 mL | 16.7051 mL | |
| 10 mM | 0.3341 mL | 1.6705 mL | 3.3410 mL | 8.3525 mL | |
| 15 mM | 0.2227 mL | 1.1137 mL | 2.2273 mL | 5.5684 mL | |
| 20 mM | 0.1671 mL | 0.8353 mL | 1.6705 mL | 4.1763 mL | |
| 25 mM | 0.1336 mL | 0.6682 mL | 1.3364 mL | 3.3410 mL | |
| 30 mM | 0.1114 mL | 0.5568 mL | 1.1137 mL | 2.7842 mL | |
| 40 mM | 0.0835 mL | 0.4176 mL | 0.8353 mL | 2.0881 mL | |
| 50 mM | 0.0668 mL | 0.3341 mL | 0.6682 mL | 1.6705 mL | |
| 60 mM | 0.0557 mL | 0.2784 mL | 0.5568 mL | 1.3921 mL | |
| 80 mM | 0.0418 mL | 0.2088 mL | 0.4176 mL | 1.0441 mL | |
| 100 mM | 0.0334 mL | 0.1671 mL | 0.3341 mL | 0.8353 mL |
PD81723 Related Classifications
HY-103188 Related Classifications
Powered by Bioz